ArticleJournal of translational medicine2026
Dynamic gut microbiota shift in chronic liver disease progression: machine learning models and the E/Er ratio as a predictive biomarker.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundChronic liver disease (CLD) and its progression to compensated cirrhosis (CC), decompensated cirrhosis (DC), and acute-on-chronic liver failure (ACLF) represent a global health crisis with high mortality. The "gut-liver axis" plays a pivotal role in this progression, yet a systematic characterization of the dynamic microbial evolution across the entire disease spectrum remains elusive. We aimed to systematically characterize the gut microbiota's dynamic evolution across the spectrum of chronic liver disease and to develop machine-learning models for predicting its critical transitions.
methodsIn this retrospective cohort study, 947 patients with liver disease (CLD, n = 464; CC, n = 159; DC, n = 260; ACLF, n = 64) were enrolled. The relative abundances of 10 dominant gut microbiota-including Enterococcus, Lactobacillus, Clostridium leptum, Clostridium butyricum, Eubacterium rectale, Faecalibacterium prausnitzii, Bacteroides, Enterobacterium, Bifidobacterium, and Atopobium cluster-were quantified via qPCR. Random Forest (RF) models were constructed to predict transitions between disease stages. The discriminatory efficacy of the Enterococcus/Eubacterium rectale Ratio (E/Er Ratio) was further evaluated using Receiver Operating Characteristic (ROC) analysis.
resultsFour distinct dynamic evolutionary patterns were identified. The pro-inflammatory/anti-inflammatory ratio increased 5.4-fold from CLD to ACLF. Random Forest models accurately predicted all disease transitions. The model for the DC-to-ACLF transition performed best (Area Under the Curve, AUC = 0.961), with clinical parameters (PT, TBil) being the strongest predictors. While the addition of microbial features yielded a modest incremental gain in AUC for the late-stage transition, indices such as the Specific-Butyrate-to-Total ratio were identified as key features, providing critical biological insights into the systemic failure of the gut-liver axis. The E/Er Ratio further served as a robust, non-invasive marker for identifying critical disease turning points.
conclusionLiver disease progression is characterized by a systematic shift in the gut microbiota from an anti-inflammatory, butyrate-rich state to a pro-inflammatory, pathogen-dominant environment. The integrated RF models and the E/Er Ratio provide a powerful, non-invasive framework for the early prediction and risk stratification of chronic liver disease progression, offering potential targets for gut-centered therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.